|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Blood, 1 February 2005, Vol. 105, No. 3, pp. 973-977. Prepublished online as a Blood First Edition Paper on September 23, 2004; DOI 10.1182/blood-2004-07-2864.
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 casesFrom the Divisions of Hematology and Internal Medicine, Hematopathology, and Laboratory Genetics and the Cancer Center Statistics Unit, Mayo Clinic, Rochester, MN.
Among 2333 consecutive patients with myelofibrosis with myeloid metaplasia (MMM) seen at our institution, 91 fulfilled the World Health Organization (WHO) criteria for leukemic transformation (LT). All episodes of LT were myeloid in origin (acute myeloid leukemia [AML]) with all French-American-British (FAB) subtypes represented except M3; the most frequent subtypes were M7 (25.4%), M0 (22.4%), and M2 (17.9%). Cytogenetic studies during LT were available in 56 patients and revealed a clonal abnormality in 51 (91%): 30 patients had complex karyotype, 2 had core-binding factor gene lesions, and 18 had abnormalities of chromosome 5 or 7. Karyotypic evolution was documented in the majority of the patients in whom serial analysis was possible. In general, LT was fatal in 98% of the cases after a median of 2.6 months (range, 0-24.2 months). Twenty-four patients received AML-like induction chemotherapy that resulted in no complete remission: 41% reverted into chronic-phase disease and the incidence of treatment-related mortality was 33%. The remaining 67 patients received either supportive care alone (48 patients) or low-intensity chemotherapy (19 patients). Overall, survival was similarly poor in all 3 treatment categories. The outcome of LT in MMM with current therapies is dismal and either supportive care alone or appropriate clinical trials should be considered.
Myelofibrosis with myeloid metaplasia (MMM) is currently classified as a myeloproliferative disorder and can present de novo (agnogenic myeloid metaplasia) or develop in the setting of either polycythemia vera (postpolycythemic myeloid metaplasia) or essential thrombocythemia (postthrombocythemic myeloid metaplasia) at a rate of 10% to 20% after 15 to 20 years of follow-up.1,2 The disease represents stem cell–derived clonal myeloproliferation that is accompanied by intense bone marrow stromal reaction including collagen fibrosis, osteosclerosis, and angiogenesis.3 Clinical manifestations include progressive anemia, massive splenomegaly, hepatosplenic as well as nonhepatosplenic extramedullary hematopoiesis, and a leukoerythroblastic blood smear.4 Average life expectancy is estimated at 5 to 7 years but may approach 15 years in young patients with good prognostic factors.5 Neither drug therapy nor allogeneic hematopoietic stem cell transplantation (AHSCT) has been shown, in a controlled setting, to positively influence survival in MMM.6 Cause of death in MMM includes leukemic transformation (LT) that occurs in 8% to 23% of patients in the first 10 years of diagnosis.7,8 Little data exist regarding the details of the pathologic and cytogenetic presentations as well as treatment outcome of LT in MMM. Patients, materials, and methods After obtaining approval from the Mayo Clinic Institutional Review Board, the study patients were retrospectively identified from our institutional database of medical diagnoses. Specifically, patients were required to have both a histologically confirmed case of MMM initially and subsequently have been evaluated at our institution between 1980 and 2003 after LT. The diagnosis and classification of LT were according to the World Health Organization (WHO) criteria (ie, 20% blasts in bone marrow or peripheral blood).9 Cases of acute myelofibrosis, overt myelodysplastic syndrome, chronic myelomonocytic leukemia, and bcr/abl-positive leukemia were excluded. Details regarding clinical and laboratory presentation during both initial diagnosis of MMM and at the time of LT were abstracted from medical records. All therapeutic interventions were recorded and assessed after the time of transformation and treatment categories included supportive care only, low-intensity chemotherapy (ie, goal of therapy was palliation rather than obtaining remission), and acute myeloid leukemia (AML)–like induction chemotherapy. Survival of LT patients was defined as the interval from the date of diagnosis of LT to either death or last contact. An event was defined as a death from any cause, unless otherwise indicated. Kaplan-Meier methodology was used to estimate survival distributions. Bone marrow histology and cytogenetic details at time of initial MMM diagnosis and LT and after therapy were rereviewed in each instance for diagnostic confirmation, French-American-British (FAB) classification of LT, myeloblast percentage, degree of reticulin fibrosis and osteosclerosis, and evidence of karyotypic evolution.
Disease information prior to leukemic transformation A total of 2333 patients with MMM were evaluated at our institution between 1980 and 2003. Among these, 91 fulfilled the WHO criteria for AML during the time of their visit at the Mayo Clinic. Among these individuals, 62 (68%) had been cared for at our institution during the chronic phase of their disease (MMM), whereas the remainder were referred at or near the time (< 2 months) of transformation. Patients who experienced LT elsewhere were not included in the current study. Patient characteristics are outlined in Table 1. The median interval between MMM diagnosis and LT was 31 months (range, 2-441 months) and the median age at transformation was 66 years (range, 41-82 years). As to be expected, most of the study patients had advanced disease at the time of LT, including the need for cytoreductive therapy in the majority, and pre-LT splenectomy was documented in 36% (Table 1). It is to be noted that 48% of the study patients had evidence of circulating blasts (a known adverse prognostic feature in MMM) at the time of MMM diagnosis.
Clinical and laboratory features during leukemic transformation All LT cases were pathologically confirmed to be myeloid in origin (AML) by direct examination of the bone marrow in 78 patients (86%) and the peripheral blood smear in the remaining 13 patients. Table 2 outlines the FAB classification details that reveal that the most frequent AML subtypes were M7, M0, and M2. However, all FAB subtypes except M3 were represented. Although an increase in circulating myeloblast percentage was prevalent (median, 25%; range, 0%-93%), LT in some patients was diagnosed by bone marrow examination in the absence of circulating blasts (Table 2). Clinically, LT was almost always accompanied by significant anemia and thrombocytopenia, contrasted by leukocytosis (Table 2). LT was also heralded by sharp progression of the disease-associated constitutional symptoms of fatigue, night sweats, involuntary weight loss, bone pain, and progression of organomegaly.
Karyotypic changes at time of initial MMM diagnosis and during leukemic transformation Karyotypic analysis was available in 32 patients at the time of initial MMM diagnosis and 56 patients at the time of LT (Table 3). Karyotype analyses were unavailable at the time of LT in 35 patients due to either lack of availability of the assay (the series begins in 1980) or insufficient numbers of metaphases obtained from their diagnostic sample for evaluation. Cytogenetic findings at time of MMM diagnosis were similar to those previously described (Table 3).11 During LT, most (n = 51; 91%) but not all patients displayed a detectable cytogenetic abnormality (Table 3). The prevalence of "favorable in AML" cytogenetic abnormalities was very low and occurred in 2 patients, one each with t(8;21)(q22;q22) and inv(16)(p13;q22), neither of whom received AML-like induction chemotherapy due to poor performance status and both expired in less than one month of supportive care. The majority of patients studied at the time of LT displayed "unfavorable in AML" cytogenetic lesions (Table 3). Twenty-eight patients had karyotype analysis performed both at the diagnosis of MMM and at LT. At diagnosis of MMM, 20 patients had either normal chromosomes or a single chromosome anomaly, whereas only 7 displayed a complex karyotype with 3 or more chromosome anomalies. However, at LT all 28 patients had abnormal karyotypes, including 17 patients with markedly complex karyotypes and only 9 with simple clonal anomalies. The recurrent numeric and structural anomalies observed at transformation to AML most frequently involved chromosomes 5, 6, 7, 8, 17, 19, and 21. Additionally, among the 26 (93%) of 28 patients whose karyotype changed from MMM to LT, 11 patients (43%) displayed evolution of an existing clone and 15 (57%) developed one or more additional abnormal clones.
Bone marrow histologic changes during leukemic transformation Serial bone marrow comparison was possible in 33 patients with the second bone marrow evaluation performed at a median of 24.5 months (range, 2.1-110.4 months) from the initial diagnosis of MMM. In general, bone marrow histology during LT displayed either a diffuse (Figure 1A-B) or focal (Figure 1D) increase in myeloblasts. In general, a substantial change in either overall bone marrow cellularity or degree of reticulin fibrosis/osteosclerosis was not evident. However, most patients displayed a change in megakaryocyte morphology as well as distribution pattern from large, round, and clumped at the time of MMM diagnosis to small, condensed, and nonclumped at the time of LT (Figure 1C,E).
Outcome and treatment of leukemic transformation Complete follow up was available in all 91 patients of which 98% (n = 89) have died from their disease- or treatment-related complications. Figure 2 outlines survival curves from time of initial MMM diagnosis (panel A), from the time of LT diagnosis (panel B), and comparison of survival curves between supportive care alone and actively treated (panel C) as well as between those who did and did not receive AML-like induction chemotherapy (panel D). Overall survival after LT was dismal with a median of 2.6 months (range, 0-24.2 months; Figure 2B). Specifically, mortality after LT (regardless of treatment intervention) was 26%, 52%, 70%, and 91% at 1, 3, 6, and 12 months, respectively, with only 2 patients (2.1%) alive with disease more than 2 years after LT and 41 and 57 months following treatment with either cytarabine-based induction chemotherapy or allogeneic transplantation.
For the purposes of discussion, we have categorized the patients into 3 treatment categories of supportive care (48 patients), low-intensity chemotherapy (19 patients), and AML-like induction chemotherapy (24 patients; Tables 4, 5). Therapy was chosen by the treating physician based upon clinical judgment and patient's performance status. Overall, survival was similarly poor in all 3 categories (Figure 2C-D). Supportive therapy included the use of erythrocyte or platelet transfusions, antibiotic therapy, and in most instances oral chemotherapy with hydroxyurea to prevent leukostasis. Median survival in this group was 2.0 months (range, 0-20.1 months). The goal of low-intensity therapy was palliation instead of remission. The treatment regimens in this regard (Table 4) were selected on the basis of performance status and patient choice. None of these low-intensity regimens produced a demonstrable and sustained response (median survival, 2.9 months; range, 0.4-22.5 months).
Twenty-four patients (26%) received AML-like induction chemotherapy (Table 4). Treatment-related mortality in this cohort was substantial (33%). Although several patients achieved posttreatment aplasia (ie, day-14 marrow after initiating therapy) without evidence of leukemia, none proceeded to complete remission. There were 10 patients (41%) who displayed posttreatment changes of bone marrow histology consistent with chronic-phase disease without an increase in blast percentage (Figure 1C,F). Among this latter group, survival after induction was a median of 6.2 months (95% confidence interval [CI] 1.4-10.9) as opposed to a median of 2.7 months (95% CI 1.1-3.6; P = not significant [NS]) for those patients who did not significantly reduce the marrow blast percentage. Additionally, among those who cleared the marrow of excess blasts (n = 10), 5 rapidly relapsed to acute leukemia whereas the rest died of end-stage MMM, profound cytopenias, or residual complications from induction. The use of either newer and presumably less toxic induction agents (gemtuzumab ozogamicin, R115777, on a clinical trial) or even autologous stem cell transplantation did not result in a better outcome. Median survival in patients receiving AML-like induction chemotherapy was 3.9 months (range, 1.6-57 months; Figure 2D).
The current study was not designed to determine the rate of LT in MMM because only patients that were evaluated at the time of the particular event were considered. Instead, a detailed account of the clinical and laboratory features of LT, in the largest cohort of MMM patients ever studied, is presented. The representative nature of the study group is reflected by the expected distribution of baseline characteristics, at initial diagnosis of MMM, in terms of prognostic score categories, age, and cytogenetic findings.10-12 The overall findings were sobering in regards to both survival and treatment response. Almost all (98%) affected patients died after a median of fewer than 3 months and not a single patient achieved complete remission from standard induction chemotherapy. Such an outcome might be considered even worse than expected from other instances of poor-risk AML and possibly related to the high incidence of AML-M7 and AML-M0.13-15 It is difficult from the current uncontrolled study to suggest risk factors for LT in MMM. However, the relatively high proportion of patients (48%) who displayed circulating blasts during the initial diagnosis of MMM raises the possibility of significant association and is consistent with the previously recognized detrimental effect of the particular laboratory trait to survival in MMM.5,7 In general, there is limited information regarding risk factors for LT in MMM but both leukocytosis and abnormal karyotype have previously been implicated.10 However, the prognostic value of cytogenetic findings in MMM has been controversial and the discrepancies from various studies might relate to the presence of prognostically diverse specific lesions.11 Karyotypic information from the current study does not necessarily implicate any one abnormality as being associated with LT in MMM but instead confirms the process of clonal evolution and the appearance of new lesions that are infrequently detected at the time of initial diagnosis. Whether such lesions impart disease-promoting activity or reflect genetic instability during clonal progression is currently not delineated. Another issue of relevance for LT in myeloproliferative disorders is its possible association with specific cytoreductive treatment agents. In the current study, 26% of patients had received potentially leukemogenic agents including radioactive phosphorus and oral alkylating agents, whereas 52% had received hydroxyurea prior to LT. However, short of a controlled study, it is difficult to separate drug leukemogenicity from disease-intrinsic clonal evolution that is associated with active disease.16 Another therapeutic modality in MMM that has been implicated in accelerating the occurrence of LT is splenectomy.17 However, the particular contention has not been supported by observations from other studies.10,18 In the current study, approximately one third of the patients with LT had been previously splenectomized without any evidence of temporal association with blastic transformation. The natural history of MMM, although quite variable depending upon presentation features, has been addressed by several large series and none have suggested the influence of treatment on either LT or survival.10,19,20 The major clinical findings from the current study demonstrate that LT in MMM usually occurs in the setting of advanced disease and is associated with dismal prognosis as well as poor response to current therapy. In particular, AML-like induction chemotherapy was associated with a high incidence of treatment-related mortality (33%) and did not appear to be superior to supportive care management. Allogeneic stem cell transplantation was used in only one patient. Age, comorbidities, organ dysfunction, lack of a suitable donor, concern of reduced efficacy of allogeneic transplantation in the setting of high disease burden, and the need for significant cytoreduction prior to transplantation limited this therapy being employed in the remaining patients. Given the poor outcomes we observed, it is indeed a small subset of patients who would (a) be a candidate for induction chemotherapy and (b) achieve a significant cytoreduction with induction and remain a candidate for transplantations after induction-related toxicities. This report is unable to address the utility of allogeneic transplantation as salvage therapy for transformed MMM. Nevertheless, our data would suggest, given the rapid mortality after LT, if a transplantation is to be considered in these patients, waiting until the time of LT is probably less than optimal. Although these observations are likely to discourage the consideration of aggressive chemotherapy in the majority of the patients, such therapy should not be discounted in the presence of either "favorable in AML" cytogenetic lesions (2 patients developed core-binding factor AML) or the possibility to offer allogenic stem cell transplantation for selected patients (41% reverted into chronicphase disease). Otherwise, participation in experimental treatment protocols is strongly advised. Ultimately, the best chance for overall success might reside in the development of effective therapy for chronic-phase disease.
Submitted July 30, 2004; accepted September 16, 2004.
Prepublished online as Blood First Edition Paper, September 23, 2004; DOI 10.1182/blood-2004-07-2864.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Ruben A. Mesa, Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905; e-mail: mesa.ruben{at}mayo.edu.
  CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top
Abstract
Introduction
